# Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-

> **NCT05140655** · — · UNKNOWN · sponsor: **Dr. Reddy's Laboratories SAS** · enrollment: 40 (estimated)

## Conditions studied

- Breast Neoplasm Female

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT05140655
- **Lead sponsor:** Dr. Reddy's Laboratories SAS
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-19
- **Primary completion:** 2022-04-19
- **Final completion:** 2022-08-19
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05140655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05140655, "Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05140655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*